<DOC>
	<DOCNO>NCT01810367</DOCNO>
	<brief_summary>Assess PFS/ORR/OS ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin first Treatment NSCLC</brief_summary>
	<brief_title>ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1.18~75 year 2.Patients diagnose histologic , cytologic diagnosis IIIbIV nonsmall cell lung cancer 3.Presence least one index lesion measurable CT scan MRI 4.Ecog01 5.Expected life time longer 12 week 6.Normal laboratory value : leucocyte ≥ 4×109/L neutrophil ≥ 1.5×109/L platelet ≥ 100×109/L Hemoglobin ≥ 10g/L ALT AST ≤ 2.5×ULN ( ≤ 5×ULN liver metastasis ) 7.Signed write informed consent Patients use drug accord protocol Patients allergic pemetrexed cisplatin Patients receive radiotherapy biological treatment 4 week trial Uncontrolled hydrothorax hydropericardium neuropathy toxicity ≥ CTC 3 Severe symptomatic heart disease Active upper gastrointestinal ulcer digestive disfunction Severe infection metabolic disfunction Patients malignant tumor Uncontrolled brain metastasis Patients accept clinical trial Female patient pregnant lactation period , patient without contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>PFS</keyword>
</DOC>